Stay updated with breaking news from While Novartis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NORTHAMPTON, MA / ACCESSWIRE / February 7, 2023 / Novartis is a focused medicines company with a purpose to reimagine medicine to improve and extend people's lives. On February 1, we published our Novartis
Zolgensma may stop five-year-old Yusuf Polat’s spinal muscular atrophy from progressing, but it costs $2.1m.
When Novartis reported first-half Zolgensma sales a few months ago, the company said its spinal muscular atrophy gene therapy was growing thanks to "expanding access" in Europe. This week at the Fierce Biotech Cell & Gene Therapy event, an exec outlined what's driving the uptake.